Left ventricular hypertrophy and arterial stiffness in essential hypertension

Yucel C¹, Demir S², Demir M³, Tufenk M⁴, Nas K⁵, Molnar F⁶, Illyes M⁷, Acarturk E¹

Cukurova University, School of Medicine, Department of Cardiology, Adana, Turkey.
demirkardiyoloji@hotmail.com

ABSTRACT

AIM: The aim of this study was to evaluate the association between an increase in arterial stiffness and the development of left ventricular hypertrophy in essential hypertension patients.

MATERIALS AND METHODS: One hundred forty essential hypertension patients were included in the study. Patients were divided into two groups based on echocardiographic measurements; with left ventricular hypertrophy (n=70) and without left ventricular hypertrophy (n=70). The criterion for hypertrophy was accepted as an intraventricular septum and posterior wall thickness in diastole of 11 mm or above. Aortic stiffness values of the patients groups were measured noninvasively by arteriography through the brachial artery. Pulse wave velocity (PWV) measurements were used as indicators of arterial stiffness.

RESULTS: When compared to the group without left ventricular hypertrophy, elevated systolic blood pressure, mean blood pressure, and pulse pressure were located in the left ventricular hypertrophy group at a significant level (p > 0.01). A statistically significant difference was not observed in the diastolic blood pressure and pulse measurements of the groups. Pulse wave velocity, the indicator of arterial stiffness, was elevated to a significant degree in the left ventricular hypertrophy group (p > 0.01). While a positive correlation was found between pulse wave velocity and left ventricle mass index, microalbuminuria, high sensitive C-reactive protein (Hs-CRP), and left ventricle end-diastolic volume, a negative correlation was found between pulse wave propagation velocity and left ventricle E/A.

CONCLUSIONS: In conclusion, pulse wave analysis is a valuable method for predicting cardiac hypertrophy in essential hypertension (Tab. 6, Ref. 25).

KEY WORDS: arterial stiffness, hypertension, left ventricular hypertrophy.

Introduction

Hypertension (HT) is a widespread and multifaceted public health issue throughout the world. Being the cause of other organ diseases, it has a significant impact on patient morbidity and mortality. Hypertension due to pressure load is a clinical indicator of progressive left ventricular hypertrophy (LVH) in hypertensive heart disease. Cardiovascular (CV) mortality risk increases approximately 7–9 fold in left ventricular hypertrophy patients (1). Arterial stiffness and pulsatile load are gradually being understood to make a significant contribution to the pathophysiology of HT and CV diseases (2). Structural changes in the vessel wall induced by the stress of high pressure due to hypertension and atherosclerosis cause aortic stiffness (3).

Particularly, the occurrence of arterial stiffness in large vessels was found to directly affect CV morbidity and mortality (4). In studies examining aortic stiffness, predominantly pulse wave velocity (PWV) and augmentation index (Aix) were used to measure the “stiffness” index by invasive or non-invasive means (5). These parameters obtained non-invasively have been shown to be similar to those obtained invasively (6).

This study aimed to evaluate the association between left ventricular hypertrophy and arterial stiffness in hypertensive patients.

Materials and methods

Hypertensive patients (n=140) who applied to our clinic and were using calcium channel blocker (amlodipine) were included in the study. Patients were divided into two groups based on echocardiographic measurements; with left ventricular hypertrophy (n=70) and without left ventricular hypertrophy (n=70). We chose amlodipine because it may have a cardiovascular protective effect in addition to its strong blood pressure-lowering action and it has been reported to have several blood pressure-independent effects, including antioxidant activity, antiproliferative effects in vascular smooth muscle cells, and enhanced production of endothelial nitric oxide (7).

Exclusion criteria

Patients who had secondary causes of hypertension (renal failure, renal artery disease, pheochromocytoma, Conn syndrome...
etc.) concomitant atrial fibrillation, frequent ventricular extra ectopic beats, hypothyroidism, hyperthyroidism, respiratory diseases (COPD, chronic bronchitis, pulmonary embolism), primary pulmonary hypertension, acute coronary syndrome within the last 2 months, isolated right heart failure, congenital cardiac diseases and advanced valvular disease (mitral stenosis, aortic stenosis and failure), other chronic systemic disorders (diabetes, cirrhosis etc v.b) were excluded from the trial. For all the patients included in the trial, data on the risk factors such as age, gender, hypertension, smoking, family history of cardiac diseases and the drugs received were recorded.

**Measurements of blood pressure and heart rate**

Blood pressure was measured with the assistance of a mercury sphygmomanometer. Pulse count was recorded by a one-minute measurement. Hypertension was defined as blood pressure $\geq 140/90$ mm Hg.

**High sensitive CRP measurement**

Serum Hs-CRP was analyzed by immunonephelometric method with Beckman Coulter kit in Beckman Immage 800 (Beckman Coulter Inc., CA, USA) nephelometer. Analytical range of serum was Hs-CRP 0.02–8.0 mg/dL (0.2–80.0 mg/L) and analytical sensitivity for HS-CRP determination was 0.02 mg/dL (0.2 mg/L).

**Microalbuminuria detection**

Microalbuminuria assessments were made at baseline A first morning voided spot urine sample for microalbumin (measured as the urinary albumin-creatinine ratio or UACR) was collected before administration of study treatment.

**Echocardiography**

All of the echocardiographic studies were performed using an Acuson Sequoia C-256 ultrasound machine. The overall, monodimensional left ventricular measurements and the bidimensional (apical 4- and 2-chamber) views were obtained according to the recommendations of the American Society of Echocardiography (8). All of the tracings were obtained and read by a single observer blinded to the clinical characteristics of the patients under observation. The presence of LVH was defined as left ventricular mass index (LVMi) $> 49.2 \text{ g/m}^2.7$ in men and $> 46.7 \text{ g/m}^2.7$ in women.

**Arterial stiffness measurement**

The Arteriograph cuff was applied on the left arm for measurement of blood pressure (BP), pulse wave propagation velocity (PWV) with the computerized portable device, Arteriograph (TensioMed Ltd.). It initially measures the BP in the upper arm oscillometrically and afterwards records a cuff pressure over the brachial artery that is 35 mm Hg in excess of the systolic blood pressure (SBP) measured. The pressure fluctuations in the brachial artery are detected by the cuff. They are passed on to the computer and recorded and analyzed as pulse waves. The difference in time between the beginning of the first wave and the beginning of the second (reflected wave) is related to the measured distance from the jugulum to the symphysis, resulting in the PWV in m/s. The software of Arteriograph decomposes the early, late systolic and diastolic waves and also determines the onset and peaks of the waves. For PWV analysis, the onsets of the waves are determined by using first and second derivatives. To intensify the signal and thus attain better differentiation of the initial wave from the reflective wave, the Arteriograph only records and analyses the pulse waves when supra-SBP of 35 mmHg has been attained.

**Statistical methods**

All analyses were performed with SPSS 16.1 statistical software package. Continuous variables in the group data are shown as mean ± standard deviation (avg ± SD). Categorical variables are given as numbers and percentages. In the paired comparison of the groups, t-test was applied as parametric tests of independent samples. Mann-Whitney U and Kruskall-Wallis tests were applied as non-parametric tests. The Chi-square test was used in the comparison of categorical variables. Parametric or non-parametric (Pearson and Spearman) correlation analysis was performed in the investigation of associations among continuous variables. Statistical significance was accepted as $p < 0.05$.

**Results**

Observing patient demographic characteristics, a larger percentage of females (67 %) was found in the LVH (–) group (p 0.001). 36 % of the LVH(+) group were females. A statistically significant difference did not exist between the groups with respect to age, smoking, BMI and HT time period (Tab. 1).

In the LVH (+) group urea, creatinine, hs-CRP, and microalbumin levels were found to be high; while serum sodium, throm-
bocyte, and e-GFR values were low. Additional patient laboratory results are summarized in Table 2.

Significantly high systolic pressure, mean blood pressure, and pulse pressure were found in the left ventricular hypertrophy group. A statistically significant difference between the groups in diastolic blood pressure and pulse was not observed (Tab. 3).

In the echocardiographic examination interventricular septum, posterior wall, left ventricular dimensions, left ventricular mass index, and left atrium diameter and volume were larger to a significant degree in the LVH (+) group. Left ventricular ejection fraction was found to be low. Mitral flow PW (pulsed wave) was assessed by Doppler. Upon investigation of echocardiographic results, deceleration time, A, and IVRT of the LVH (+) group were greater to a significant degree; while E/A ratios and E were smaller (Tab. 4).

Arterial stiffness, indicated with PWV values, was higher at a statistically significant level in the group with left ventricular hypertrophy compared to the group without left ventricular hypertrophy (Tab. 5).

Positive correlations were found between PWV and left ventricular mass index, left atrium end-diastolic volume, hs-CRP, and microalbuminuria. A negative correlation was found between PWV and e-GFR, and the E/A ratio (Tab. 6).

### Discussion

The primary finding of this study was the identification of an association between increased arterial stiffness, measured with PWV, and target organ damage. There is a growing understanding of the substantial contribution of arterial stiffness and pulsatile load on cardiovascular patients, HT, and heart failure pathophysiology (3). It was shown that increased conduit vessel stiffness results in elevated pulse wave velocity, and the wave’s reflection in systole rather than diastole. While waves are reflected back in systole, forward waves are weakened and forward directed flow and pulse volume are reduced. The additional load placed on the fragile left ventricle triggers decompensation and arrhythmia (8–10). Furthermore, it has been demonstrated in animal models that the drift of retroreflective waves from diastole to systole causes ischemia in the presence or absence of epicardial stenosis (11).

Increased systolic blood pressure from arterial stiffness raises left ventricular afterload, which in turn raises myocardial workload and reduces diastolic blood pressure, thus impairing coronary perfusion and ultimately leading to subendocardial ischemia and fibrosis. A strong association has been demonstrated between increased arterial stiffness and target organ damage. Moreover, increased pulse wave velocity has been shown to be closely linked to CV mortality (11, 12). In systemic arterial hypertension, myocyte hypertrophy is induced by elevated afterload and activated neuro-hormonal mechanisms. Cardiac fibrosis ensues in intramyocardial coronary arteries as a result of medial hypertrophy and collagen deposition. These modifications lead to left ventricular hypertrophy. Left ventricular hypertrophy is an independent predictor of morbidity and mortality in hypertensive patients. It predisposes patients to congestive heart failure, ischemic stroke, atrial fibrillation, ventricular tachycardia, and embolic stroke (13, 14). A study by Giovanna Leoncini et al. found a significant positive association between increased arterial stiffness and left ventricular mass index (13). An association was identified by Nitta et al between left ventricular hypertrophy, elevated arterial stiffness, and vascular calcification in hemodialysis patients (15). A statistically significant increase in PWV and Aix was confirmed in the left ventricular hypertrophy hypertensive group compared to the group without left ventricular hypertrophy. In a Framingham study a significant association was identified between left ventricular hypertrophy and systolic hypertension (16). In our study, systolic and mean blood pressure, as well as pulse pressure were found to be higher at a significant level in the group with developing LVH and elevated left ventricular mass index. However, a difference between the groups in diastolic blood pressure was not observed. Left ventricular systolic and diastolic malfunction in heart failure are important factors in lifespan. Diastolic function is thought to be more greatly impaired in patients with left ventricular hypertrophy (17). Compared to the hypertension group without hypertrophy, the diastolic dysfunction indicator in the left ventricular hypertrophy group was associated with multiple echocardiographic parameters at a statistically significant level. In the LVH (+) group PWV, left ventricular mass index, and left atrium end-diastolic volume were positively associated. On the other hand, PWV was negatively associated with the E/A ratio.
Being associated with many metabolic and non-metabolic risk factors, microalbuminuria is a common microvascular damage indicator independent of other risk factors in patients with essential HT, and is estimated as the primary determinant of CV mortality. Pontremoli et al. reported in a study of 787 patients with essential HT that the association between the incidence of microalbuminuria and the development of CV disease could indicate urinary albumin excretion as a reliable marker in the diagnosis of CV (16). In a study of 205 essential HT patients, Tsai et al. found that arterial stiffness was greater to a statistically significant degree in the group with LVH and proteinuria (19). Consequently, measurement of urinary albumin excretion is critical for hypertensive patients (20). In the Cerasola et al. study, it was found that patients with microalbuminuria had a higher blood pressure and peripheral PWV in 24 hours. In our study microalbuminuria was high in the LVH(+) group, and was positively correlated with PWV.

Regardless of the presence of other risk factors, high hs-CRP values are independently accompanied by increased risk of CV event (21–22). Kampus et al found that with Aix increase, hs-CRP, and leukocyte count were positively associated (23). Rotterdam event (21–22). Kampus et al found that with Aix increase, hs-CRP, and leukocyte count were positively associated (23). Rotterdam event.

In our study as well, the hs-CRP level was high in patients (25). In our study, target organ damage was determined in left ventricular hypertrophy patients with elevated arterial stiffness. In conclusion, pulse wave analysis is a valuable method in predicting cardiac hypertrophy in essential hypertension. Arterial stiffness should be taken into account when planning therapeutic strategies for prevention of left ventricular hypertrophy in hypertensive patients (25). In our study as well, the hs-CRP level was high in patients with LVH, and a significant correlation between PWV and hs-CRP level was identified.

Conclusion

In our study, target organ damage was determined in left ventricular hypertrophy patients with elevated arterial stiffness. In conclusion, pulse wave analysis is a valuable method in predicting cardiac hypertrophy in essential hypertension. Arterial stiffness should be taken into account when planning therapeutic strategies for prevention of left ventricular hypertrophy in hypertensive patients.

Limitations

One hundred forty patients were included in our study. Therefore, studies with larger sample sizes are needed. This is a cross-sectional study. Longitudinal studies are needed to determine the relation between PWV and left ventricular hypertrophy.

References


Received February 2, 2015.
Accepted February 15, 2015.